Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2024-04-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
关于修订《公司章程》并办理工商变更登记手续的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Hangzhou Anxu Biotechnology Co., Ltd. regarding the revision of the company's Articles of Association (公司章程) and the related procedures for industrial and commercial registration changes. It includes extensive details about the amendments to the Articles of Association, especially concerning the nomination, duties, and rights of independent directors, board structure, and governance rules. The document states that the amendments will be submitted to the shareholders' meeting for approval and that the final changes will be subject to approval by the industrial and commercial registration authority. The document is not a full annual report, audit report, or financial statement. It is not a call transcript, earnings release, or capital update. Instead, it is a regulatory announcement about governance changes and corporate charter amendments. This fits best under the category of Regulatory Filings (RNS), as it is a compliance and governance-related announcement that does not fit other more specific categories. The document length (over 11,000 characters) and detailed content confirm it is not a mere report publication announcement but a substantive regulatory filing.
2024-04-29 Chinese
中审众环会计师事务所（特殊普通合伙）关于安旭生物非经营性资金占用及其他关联资金往来情况的专项审核报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审计报告" which translates to a "special audit report" concerning non-operating fund occupation and other related party fund transactions for Hangzhou Anxu Biotechnology Co., Ltd. It includes detailed tables and data about fund usage and related party transactions for the year 2023. The content is a standalone audit report focusing on specific audit matters rather than a full annual report or interim report. The document length is 2711 characters, which is relatively short but contains substantive audit findings and data, not merely an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2023
2024-04-29 Chinese
2023年度独立董事述职报告（周娟英）
Management Reports Classification · 95% confidence The document is titled as an independent director's annual report for the year 2023 from Hangzhou Anxu Biotechnology Co., Ltd. It details the independent director's duties, attendance at board and committee meetings, communication with auditors, and oversight activities during the year. It includes information on governance, compliance with laws and regulations, and evaluations of company practices. The content is a detailed management report on the independent director's activities and oversight for the year, not a full annual report or financial statement. It is not a simple announcement or certification but a substantive report on management and governance activities. Therefore, the document fits best under the category of Management Reports (MDA).
2024-04-29 Chinese
关于2024年度“提质增效重回报”行动方案的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors of Hangzhou Anxu Biotechnology Co., Ltd. regarding the company's 2024 action plan titled 'Quality Improvement, Efficiency Enhancement, and Return to Shareholders.' It outlines strategic initiatives, business focus, production capacity expansion, governance improvements, investor communication, dividend policy, and management compensation. The document is a formal announcement of a corporate plan and governance-related information rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data. The length is about 3,097 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other specific categories.
2024-04-29 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policy by the company Hangzhou Anxu Biotechnology Co., Ltd. It references a new accounting standard interpretation issued by the Ministry of Finance of China and explains the nature and impact of the accounting policy change. The document is relatively short (1271 characters) and does not contain financial statements or detailed financial data. It is a regulatory announcement about accounting policy changes rather than a full audit report or annual/interim report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-29 Chinese
中审众环会计师事务所（特殊普通合伙）关于安旭生物2023年度审计报告
Regulatory Filings
2024-04-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.